Navigation Links
Angioplasty death risk reduced by doubling drug dose

A new study shows how the risk of death and heart attack can be reduced for heart patients undergoing an angioplasty.// It was found that doubling the usual dose of an anti-clotting drug before the procedure is the answer.

Angioplasty is a procedure in which a balloon-tipped catheter is threaded into an artery. The balloon is inflated to compress plaque in the artery and unblock the vessel. A small synthetic tube - stent is used to hold the vessel open, but arteries often re-close if blood clots form to protect the body against bleeding.

Patients commonly take the drug clopidogrel (Plavix) before angioplasty to prevent clotting. In this new study, patients received either the standard dose of 300 milligrams or received a dose of 600 milligrams before the procedure.

Following angioplasty it was found out that, 12 percent of patients who took the lower dose died, had a heart attack or needed another procedure. In contrast, only 4 percent of patients in the high-dose group had such an event. Doubling the dosage did not increase the risk of bleeding.

In conclusion, it was evident that the high-dose patients had a 48-percent reduction in heart attack risk compared to those given the standard dose. Additionally, a subgroup of patients taking the higher dose as well as the cholesterol-lowering drugs called statins had an 80-percent reduction.
'"/>




Page: 1

Related medicine news :

1. Cholesterol Drug Helps After Angioplasty
2. Angioplasty Should be the Standard
3. The Success Rate Of Angioplasty In Female Patients Low
4. Angioplasty The Much Preferred Treatment Of Choice For Heart Attacks
5. Angioplasty death risk reduced by doubling drug dose
6. A ray of hope in Angioplasty dilemma
7. Angioplasty plus stenting better than thrombolysis for elderly patients with AMI
8. Patients Fare Better With Doctors Who Do More Angioplasty Procedures
9. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Togadiyas Condition Stable After Undergoing Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: